🇺🇸 FDA
Patent

US 9353108

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

granted A61PA61P3/00A61P3/10

Quick answer

US patent 9353108 (Tetrahydronaphthyridine somatostatin receptor 5 antagonists) held by Takeda Pharmaceutical Company Limited expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P3/00, A61P3/10, A61P43/00, A61P9/00